Orale Antikoagulation nach Klappeneingriffen – Was ist der Standard?

Konstantin Stark; Steffen Massberg

doi:10.1055/a-1911-4911

Aktuelle Kardiologie, Table of Contents

Aktuelle Kardiologie 2022; 11(05): 477-483
DOI: 10.1055/a-1911-4911

Kurzübersicht

Orale Antikoagulation nach Klappeneingriffen – Was ist der Standard?

Standards in Oral Anticoagulation after Percutaneous Valve Interventions

Konstantin Stark

¹Medizinische Klinik und Poliklinik I – Campus Großhadern, LMU Klinikum der Universität München, München, Deutschland

,

Steffen Massberg

¹Medizinische Klinik und Poliklinik I – Campus Großhadern, LMU Klinikum der Universität München, München, Deutschland

²Medizinische Klinik und Poliklinik I – Campus Innenstadt, LMU Klinikum der Universität München, München, Deutschland

› Author Affiliations

Abstract

Zusammenfassung

Nach interventionellen Eingriffen an der Aortenklappe oder den atrioventrikulären (AV) Klappen (u. a. TAVI, M-TEER, T-TEER) wird prinzipiell eine antithrombotische Therapie empfohlen. Dabei muss differenziert werden zwischen Patienten, für die unabhängig vom Klappeneingriff eine Indikation zur oralen Antikoagulation (OAC) besteht, meist aufgrund von Vorhofflimmern (AF), und Patienten ohne OAC-Indikation. Mehrere randomisierte Studien konnten zeigen, dass bei AF-Patienten, die eine TAVI erhalten, eine Fortführung der OAC (Vitamin-K-Antagonisten oder NOAC) als Monotherapie einer dualen Therapie, bestehend aus OAC plus zusätzliche Thrombozyteninhibition, überlegen ist. Andererseits ist bei TAVI-Patienten ohne vorbestehende OAC-Indikation eine ASS-Monotherapie als postinterventionelle antithrombotische Therapie zu empfehlen. Nach segelbasierter (Edge-to-Edge) Rekonstruktion der Mitral- und Trikuspidalklappe wird bei bestehender OAC-Indikation eine Fortsetzung der Antikoagulation empfohlen, ansonsten ASS dauerhaft mit Clopidogrel für 1–3 Monate. Die optimale antithrombotische Therapie im Kontext interventioneller Eingriffe an den AV-Klappen ist jedoch bislang nicht in größeren randomisierten Studien untersucht.

Abstract

After interventional procedures of the aortic or the atrioventricular (AV) valves (e.g. TAVI, M-TEER, T-TEER), antithrombotic therapy is recommended. When choosing the optimal antithrombotic regimen, a distinction must be made between patients that have an indication for an oral anticoagulation (OAC) that exists independent of the valve intervention, mostly atrial fibrillation (AF), and patients without such an indication. Several randomized trials have shown that in AF patients receiving TAVI, continuation of OAC (vitamin K antagonists or NOAC) as monotherapy is superior to dual therapy consisting of OAC plus additional anti-platelet therapy. On the other hand, in TAVI patients without preexisting OAC indication, aspirin monotherapy is recommended as postinterventional antithrombotic therapy. After edge-to-edge repair of the mitral and tricuspid valves, continued OAC is recommended if there is a preexisting indication, otherwise aspirin should be prescribed permanently plus clopidogrel for 1–3 months. However, the optimal antithrombotic therapy after interventional repair and replacement of atrioventricular valves has not yet been investigated in larger randomized trials.

Schlüsselwörter

Antikoagulation - TAVI - interventionelle Klappeneingriffe - Edge-to-Edge-Rekonstruktion

Keywords

anticoagulation - TAVR - percutaneous valve interventions - edge-to-edge repair

Full Text

References

Literatur
1 Leon MB, Smith CR, Mack MJ. et al. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med 2016; 374: 1609-1620
2 Smith CR, Leon MB, Mack MJ. et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011; 364: 2187-2198
3 Ten Berg J, Sibbing D, Rocca B. et al. Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease. Eur Heart J 2021; 42: 2265-2269
4 Vahanian A, Beyersdorf F, Praz F. et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2022; 43: 561-632
5 Hochholzer W, Nührenberg T, Flierl U. Antithrombotische Therapie nach strukturellen kardialen Interventionen. Kardiologe 2021; 15: 57-70
6 Nijenhuis VJ, Brouwer J, Delewi R. et al. Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. N Engl J Med 2020; 382: 1696-1707
7 Abdul-Jawad Altisent O, Durand E, Muñoz-García AJ. et al. Warfarin and Antiplatelet Therapy Versus Warfarin Alone for Treating Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv 2016; 9: 1706-1717
8 Hindricks G, Potpara T, Dagres N. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42: 373-498
9 Ruff CT, Giugliano RP, Braunwald E. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955-962
10 Jochheim D, Barbanti M, Capretti G. et al. Oral Anticoagulant Type and Outcomes After Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv 2019; 12: 1566-1576
11 Collet JP, Van Belle E, Thiele H. et al. Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial. Eur Heart J 2022; 43: 2783-2797
12 Van Mieghem NM, Unverdorben M, Hengstenberg C. et al. Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR. N Engl J Med 2021; 385: 2150-2160
13 Giugliano RP, Ruff CT, Braunwald E. et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-2104
14 Chakravarty T, Søndergaard L, Friedman J. et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet 2017; 389: 2383-2392
15 Ueyam H, Kuno T, Ando T. et al. Meta-analysis Comparing Direct Oral Anticoagulants Versus Vitamin K Antagonists After Transcatheter Aortic Valve Implantation. Am J Cardiol 2020; 125: 1102-1107
16 Arora S, Vemulapalli S, Stebbins A. et al. The Prevalence and Impact of Atrial Fibrillation on 1-Year Outcomes in Patients Undergoing Transcatheter Mitral Valve Repair: Results From the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. JACC Cardiovasc Interv 2019; 12: 569-578
17 Nickenig G, Weber M, Lurz P. et al. Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation: 6-month outcomes of the TRILUMINATE single-arm study. Lancet 2019; 394: 2002-2011
18 Praz F, Spargias K, Chrissoheris M. et al. Compassionate use of the PASCAL transcatheter mitral valve repair system for patients with severe mitral regurgitation: a multicentre, prospective, observational, first-in-man study. Lancet 2017; 390: 773-780
19 Stone GW, Lindenfeld J, Abraham WT. et al. Transcatheter Mitral-Valve Repair in Patients with Heart Failure. N Engl J Med 2018; 379: 2307-2318
20 Donal E, Leurent G, Ganivet A. et al. Multicentric randomized evaluation of a tricuspid valve percutaneous repair system (clip for the tricuspid valve) in the treatment of severe secondary tricuspid regurgitation Tri.Fr Design paper. Eur Heart J Cardiovasc Imaging 2021;
21 Praz F, Muraru D, Kreidel F. et al. Transcatheter treatment for tricuspid valve disease. EuroIntervention 2021; 17: 791-808
22 Webb JG, Ming-Yu Chuang A, Meier D. et al. Transcatheter Tricuspid Valve Replacement With the EVOQUE System: 1-Year Outcomes of a Multicenter, First-in-Human Experience. JACC Cardiovasc Interv 2022; 15: 481-491
23 Feldman T, Foster E, Glower DD. et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med 2011; 364: 1395-1406
24 Makkar RR, Fontana G, Jilaihawi H. et al. Possible Subclinical Leaflet Thrombosis in Bioprosthetic Aortic Valves. N Engl J Med 2015; 373: 2015-2024
25 Dangas GD, Tijssen JGP, Wöhrle J. et al. A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. N Engl J Med 2020; 382: 120-129
26 Brouwer J, Nijenhuis VJ, Delewi R. et al. Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. N Engl J Med 2020; 383: 1447-1457
27 Orban M, Braun D, Sonne C. et al. Dangerous liaison: successful percutaneous edge-to-edge mitral valve repair in patients with end-stage systolic heart failure can cause left ventricular thrombus formation. EuroIntervention 2014; 10: 253-259
28 Pagnesi M, Moroni F, Beneduce A. et al. Thrombotic Risk and Antithrombotic Strategies After Transcatheter Mitral Valve Replacement. JACC Cardiovasc Interv 2019; 12: 2388-2401
29 Del Val D, Nunes Ferreira-Neto A, Wintzer-Wehekind J. et al. Early Experience With Transcatheter Mitral Valve Replacement: A Systematic Review. J Am Heart Assoc 2019; 8: e013332
30 Fam NP, von Bardeleben RS, Hensey M. et al. Transfemoral Transcatheter Tricuspid Valve Replacement With the EVOQUE System: A Multicenter, Observational, First-in-Human Experience. JACC Cardiovasc Interv 2021; 14: 501-511
31 Davidson CJ, Lim DS, Smith RL. et al. Early Feasibility Study of Cardioband Tricuspid System for Functional Tricuspid Regurgitation: 30-Day Outcomes. JACC Cardiovasc Interv 2021; 14: 41-50
32 Maisano F, Taramasso M, Nickenig G. et al. Cardioband, a transcatheter surgical-like direct mitral valve annuloplasty system: early results of the feasibility trial. Eur Heart J 2016; 37: 817-825
33 Messika-Zeitoun D, Nickenig G, Latib A. et al. Transcatheter mitral valve repair for functional mitral regurgitation using the Cardioband system: 1 year outcomes. Eur Heart J 2019; 40: 466-472
34 Urena M, Brochet E, Lecomte M. et al. Clinical and haemodynamic outcomes of balloon-expandable transcatheter mitral valve implantation: a 7-year experience. Eur Heart J 2018; 39: 2679-2689
35 Pache G, Schoechlin S, Blanke P. et al. Early hypo-attenuated leaflet thickening in balloon-expandable transcatheter aortic heart valves. Eur Heart J 2016; 37: 2263-2271
36 Rosseel L, De Backer O, Søndergaard L. Clinical Valve Thrombosis and Subclinical Leaflet Thrombosis Following Transcatheter Aortic Valve Replacement: Is There a Need for a Patient-Tailored Antithrombotic Therapy?. Front Cardiovasc Med 2019; 6: 44
37 Makkar RR, Blanke P, Leipsic J. et al. Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Valves: PARTNER 3 Cardiac Computed Tomography Substudy. J Am Coll Cardiol 2020; 75: 3003-3015
38 De Backer O, Dangas GD, Jilaihawi H. et al. Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement. N Engl J Med 2020; 382: 130-139
39 Park W, Ahn JM, Kang DY. et al. Edoxaban versus Dual Antiplatelet Therapy for Leaflet Thrombosis and Cerebral Thromboembolism after TAVR: The ADAPT-TAVR Randomized Clinical Trial. Circulation 2022;